Evidence map›Paper›PMID 28606235›Full record

Trial reportZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2017

[Clinical effects of different therapeutic regimens for Helicobacter pylori infection in children].

Xiang-Li Zhu, Zheng Liu, Zhong-Qiang Wu, Dong Li, Ai-Ping Jiang, Gui-Xia Yu

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. World journal of clinical pediatrics · 2026
    Article
  3. Sequential versus Standard Triple Therapy for First-LineAntibiotics (Basel, Switzerland) · 2024
    Review
  4. Probiotics and autoprobiotics for treatment ofWorld journal of clinical cases · 2023
    Review
  5. Comparison of multiple treatment regimens in children withFrontiers in cellular and infection microbiology · 2023
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiang-Li ZhuDepartment of Pediatrics, Tai'an Maternal and Child Health Care Hospital, Tai'an, Shandong 271000, China. 1850360706@qq.com.
Zheng Liu
Zhong-Qiang Wu
Dong Li
Ai-Ping Jiang
Gui-Xia Yu
Taiyuan Maternity and Child Care Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the clinical effects of sequential therapy, triple therapy, sequential therapy combined with Lactobacillus, and triple therapy combined with Lactobacillus in the eradication of Helicobacter pylori (H.pylori) infection in children.

methodsA total of 416 children with H.pylori infection were randomly assigned to sequential group (102 children), triple group (100 children), sequential-Lactobacillus group (109 children), and triple-Lactobacillus group (105 children). The clinical outcome, H.pylori eradication rate, cost-effect ratio, and incidence of adverse events were compared between the four groups.

resultsThe sequential-Lactobacillus and triple-Lactobacillus groups had significantly better clinical outcomes than the sequential group and the triple group (P<0.05). The sequential-Lactobacillus group had the highest marked response rate, followed by the triple-Lactobacillus group. The triple group had the lowest marked response rate. The sequential-Lactobacillus group also had the highest H.pylori eradication rate, followed by the triple-Lactobacillus group. The triple group had the lowest H.pylori eradication rate (P<0.05). The sequential group had the lowest cost-effect ratio, followed by the sequential-Lactobacillus group. The triple group had the highest cost-effect ratio (P<0.01). The sequential-Lactobacillus group had the lowest incidence rate of adverse events, followed by the triple-Lactobacillus group. The triple group had the highest incidence rate.

conclusionsSequential therapy combined with Lactobacillus seems to be the best regimen for the eradication of H.pylori infection in children.

Indexed as

Helicobacter pyloriLactobacillusAdolescentChildChild, PreschoolFemaleHelicobacter InfectionsHumansMaleProbiotics

Identifiers

PMID28606235
PMCPMC7390303
OpenAlexW2918309035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.